Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lymphotoxin beta (None officially standardized)
- Target
- None officially standardized
- Molecular classification
- Tumor Necrosis Factor Superfamily, Type II transmembrane protein, Ligand
01
Overview
Lymphotoxin beta (LTβ), also known as TNFC, TNFSF3, or p33, is a type II membrane protein and a member of the tumor necrosis factor (TNF) superfamily. It forms heterotrimers with lymphotoxin alpha (LTα), primarily as an LTα1/β2 complex, which serves as the main ligand for the lymphotoxin beta receptor (LTβR). LTβ plays a critical role in the development and organization of secondary lymphoid tissues, induces inflammatory responses, and is implicated in tumorigenesis and chronic inflammatory diseases. Its signaling involves activation of NFκB pathways and regulation of chemokines and cytokines.
- Other names
- TNFCTNFSF3p33LTB
02
Mechanism of action
Not applicable, LTβ is a ligand, not a target for direct drug interaction. Therapeutic strategies might target the LTβ/LTβR pathway indirectly.
03
Biological functions
Immune response regulationDevelopment of secondary lymphoid tissuesAnchoring lymphotoxin-alphaInflammatory response inductionChemokine expression regulationCytokine expression regulationAdhesion molecule expression regulationActivation of NFκB pathways (canonical and alternative)
04
Disease associations
Defective development/maintenance of secondary lymphoid organsChronic inflammationTumorigenesis/carcinogenesisHepatic regeneration/lipid metabolism disorders
05
Safety considerations
Dysregulation can lead to chronic inflammationOverexpression linked to tumor growth and metastasisTargeting may disrupt normal lymphoid organ development
Beyond the preview
Go deeper on Lymphotoxin beta (None officially standardized).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lymphotoxin beta (None officially standardized).